Virulence factors and antimicrobial resistance of uropathogenic Escherichia coli (UPEC) isolated from urinary tract infections: a systematic review and meta-analysis.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
04 Aug 2021
Historique:
received: 10 03 2021
accepted: 13 07 2021
entrez: 5 8 2021
pubmed: 6 8 2021
medline: 25 9 2021
Statut: epublish

Résumé

Uropathogenic Escherichia coli (UPEC) are amongst the most frequent causes of urinary tract infections. We report a systematic review and meta-analysis of virulence factors and antimicrobial resistance of UPEC isolated from urinary tract infections. A systematic review and meta-analysis were performed using PRISMA guidelines (Research Registry ref. 5874). Data were extracted from PubMed/MEDLINE and ScienceDirect databases for studies published from January 1, 2000 to December 31, 2019. Studies reporting antimicrobial resistance and virulence factors of UPEC isolated in confirmed urinary tract infections (≥10 Our search returned 2504 hits, of which 13 studies were included in the meta-analysis, totalling 1888 UPEC isolates. Highest antimicrobial resistance rates were observed among the antibiotic class of tetracycline in 69.1% (498/721), followed by sulphonamides in 59.3% (1119/1888), quinolones in 49.4% (1956/3956), and beta-lactams in 36.9% (4410/11964). Among beta-lactams, high resistance was observed in aminopenicillins in 74.3% (1157/1557) and first generation cephalosporins in 38.8% (370/953). Meanwhile, virulence factors with highest prevalence were immune suppressors (54.1%) followed by adhesins (45.9%). Taken individually, the most observed virulence genes were shiA (92.1%), CSH (80.0%), fimH/MSHA (75.3%), traT (75.1%), sisA (72.2%), iucD (65.7%), iutA (61.8%), kpsMTII (60.6%), and PAI (55.2%). The increased antibiotic resistance of UPEC isolates was demonstrated and suggested a need for reassessment of empirical therapies in urinary tract infections treatment caused by this pathogen. In addition, this pathotype exhibited diverse surface and secreted virulence factors.

Sections du résumé

BACKGROUND BACKGROUND
Uropathogenic Escherichia coli (UPEC) are amongst the most frequent causes of urinary tract infections. We report a systematic review and meta-analysis of virulence factors and antimicrobial resistance of UPEC isolated from urinary tract infections.
METHODS METHODS
A systematic review and meta-analysis were performed using PRISMA guidelines (Research Registry ref. 5874). Data were extracted from PubMed/MEDLINE and ScienceDirect databases for studies published from January 1, 2000 to December 31, 2019. Studies reporting antimicrobial resistance and virulence factors of UPEC isolated in confirmed urinary tract infections (≥10
RESULTS RESULTS
Our search returned 2504 hits, of which 13 studies were included in the meta-analysis, totalling 1888 UPEC isolates. Highest antimicrobial resistance rates were observed among the antibiotic class of tetracycline in 69.1% (498/721), followed by sulphonamides in 59.3% (1119/1888), quinolones in 49.4% (1956/3956), and beta-lactams in 36.9% (4410/11964). Among beta-lactams, high resistance was observed in aminopenicillins in 74.3% (1157/1557) and first generation cephalosporins in 38.8% (370/953). Meanwhile, virulence factors with highest prevalence were immune suppressors (54.1%) followed by adhesins (45.9%). Taken individually, the most observed virulence genes were shiA (92.1%), CSH (80.0%), fimH/MSHA (75.3%), traT (75.1%), sisA (72.2%), iucD (65.7%), iutA (61.8%), kpsMTII (60.6%), and PAI (55.2%).
CONCLUSIONS CONCLUSIONS
The increased antibiotic resistance of UPEC isolates was demonstrated and suggested a need for reassessment of empirical therapies in urinary tract infections treatment caused by this pathogen. In addition, this pathotype exhibited diverse surface and secreted virulence factors.

Identifiants

pubmed: 34348646
doi: 10.1186/s12879-021-06435-7
pii: 10.1186/s12879-021-06435-7
pmc: PMC8336361
doi:

Substances chimiques

Anti-Bacterial Agents 0
Virulence Factors 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

753

Subventions

Organisme : ACEPHEM
Organisme : MLW-Core training
ID : 206545/Z/17/Z

Informations de copyright

© 2021. The Author(s).

Références

Clin Microbiol Rev. 2013 Apr;26(2):185-230
pubmed: 23554414
Clin Infect Dis. 2001 Nov 15;33(10):1682-6
pubmed: 11595990
Nat Rev Microbiol. 2004 Feb;2(2):123-40
pubmed: 15040260
Nat Commun. 2019 Oct 23;10(1):4828
pubmed: 31645551
PLoS One. 2011 Mar 25;6(3):e18063
pubmed: 21464963
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
Antimicrob Resist Infect Control. 2018 Oct 3;7:118
pubmed: 30305891
Afr J Infect Dis. 2013;7(1):1-7
pubmed: 24381720
Jundishapur J Microbiol. 2015 Feb 07;8(2):e17514
pubmed: 25825647
Clin Microbiol Infect. 2006 Dec;12(12):1199-206
pubmed: 17121626
J Antimicrob Chemother. 2010 Dec;65(12):2518-29
pubmed: 20935300
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
Antimicrob Agents Chemother. 2006 Feb;50(2):649-53
pubmed: 16436722
Infect Immun. 2001 Oct;69(10):6179-85
pubmed: 11553558
Mol Microbiol. 1997 Mar;23(6):1089-97
pubmed: 9106201
J Med Microbiol. 2015 Aug;64(8):828-835
pubmed: 26293926
Curr Opin Gastroenterol. 2004 Nov;20(6):565-71
pubmed: 15703684
Microbiol Mol Biol Rev. 2009 Dec;73(4):750-74
pubmed: 19946140
Trop Biomed. 2018 Mar 1;35(1):195-204
pubmed: 33601792
Sci Rep. 2016 Apr 14;6:24099
pubmed: 27076285
J Antimicrob Chemother. 2008 Jan;61(1):54-8
pubmed: 17981835
Clin Microbiol Rev. 2002 Oct;15(4):647-79
pubmed: 12364374
J Clin Epidemiol. 2014 Aug;67(8):897-903
pubmed: 24794697
Ann Clin Microbiol Antimicrob. 2018 Feb 9;17(1):3
pubmed: 29422058
Biomed Res Int. 2018 Sep 26;2018:7656752
pubmed: 30356438
Infect Immun. 1991 Jul;59(7):2311-5
pubmed: 1675626
J Infect Dis. 2017 Feb 15;215(suppl_1):S9-S17
pubmed: 28375515
Infect Immun. 2009 Dec;77(12):5322-33
pubmed: 19797063
Nat Rev Urol. 2020 Aug;17(8):439-458
pubmed: 32661333
Front Microbiol. 2017 Aug 15;8:1566
pubmed: 28861072
J Antibiot (Tokyo). 2014 Dec;67(12):799-805
pubmed: 24984795
J Med Microbiol. 2002 Feb;51(2):138-142
pubmed: 11863265
Int J Nephrol. 2012;2012:681473
pubmed: 22506110
Ann Clin Microbiol Antimicrob. 2018 Jul 24;17(1):34
pubmed: 30041652
J Infect Dis. 2002 Oct 1;186(7):1039-42
pubmed: 12232848
Enferm Infecc Microbiol Clin. 2017 Aug - Sep;35(7):426-433
pubmed: 27048964
Genet Mol Res. 2011 Oct 31;10(4):4114-25
pubmed: 22057993
Clin Microbiol Rev. 2018 Aug 1;31(4):
pubmed: 30068738
Ann Clin Lab Sci. 2010 Fall;40(4):361-7
pubmed: 20947811
PLoS Pathog. 2018 Dec 13;14(12):e1007457
pubmed: 30543708
Virulence. 2013 Jul 1;4(5):354-65
pubmed: 23611873
Turk J Med Sci. 2019 Feb 11;49(1):361-367
pubmed: 30761847
Virulence. 2012 Jan-Feb;3(1):18-28
pubmed: 22286707
Gut Pathog. 2019 Feb 21;11:10
pubmed: 30828388
Plasmid. 2008 Jul;60(1):1-18
pubmed: 18440635
Osong Public Health Res Perspect. 2015 Aug;6(4):261-8
pubmed: 26473094
BMC Microbiol. 2019 Sep 2;19(1):204
pubmed: 31477018
FEMS Microbiol Lett. 2005 Nov 15;252(2):183-90
pubmed: 16165319
Microbiology (Reading). 2005 Apr;151(Pt 4):1095-1111
pubmed: 15817778
BMC Infect Dis. 2015 Jun 09;15:224
pubmed: 26054866
Rev Soc Bras Med Trop. 2019 Jun 27;52:e20180499
pubmed: 31271618
BMC Infect Dis. 2019 Feb 11;19(1):137
pubmed: 30744567
Antimicrob Agents Chemother. 2009 Jun;53(6):2227-38
pubmed: 19307361
J Clin Diagn Res. 2012 Dec;6(10):1699-703
pubmed: 23373032
Turk J Med Sci. 2016 Dec 20;46(6):1908-1914
pubmed: 28081347
Microbiol Spectr. 2015 Aug;3(4):
pubmed: 26350328
BMC Infect Dis. 2018 Nov 15;18(1):572
pubmed: 30442101
Indian J Med Microbiol. 2008 Jan-Mar;26(1):68-70
pubmed: 18227603
Antimicrob Agents Chemother. 2005 Nov;49(11):4667-70
pubmed: 16251310

Auteurs

Gabriel Kambale Bunduki (GK)

Department of Pathology, Kamuzu University of Health Sciences (former College of Medicine/University of Malawi), Blantyre, Malawi. gbunduki@mlw.mw.
Africa Centre of Excellence in Public Health and Herbal Medicine (ACEPHEM), Blantyre, Malawi. gbunduki@mlw.mw.
Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. gbunduki@mlw.mw.
Department of Infectious Diseases, Faculty of Medicine, Université Catholique du Graben, Butembo, Democratic Republic of the Congo. gbunduki@mlw.mw.

Eva Heinz (E)

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.

Vincent Samuel Phiri (VS)

Department of Public Health, Kamuzu University of Health Sciences (former College of Medicine/University of Malawi), Blantyre, Malawi.

Patrick Noah (P)

Department of Surgery, Queen Elizabeth Central Hospital, Blantyre, Malawi.

Nicholas Feasey (N)

Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.

Janelisa Musaya (J)

Department of Pathology, Kamuzu University of Health Sciences (former College of Medicine/University of Malawi), Blantyre, Malawi.
Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH